The Department of Health and Human Services Office of Inspector General Feb. 18 released a report that found about 40% of Medicare enrollees who began opioid use disorder treatment with buprenorphine continued with it for at least six months in office-based settings. Those who did not continue treatment were more likely to have died for any cause during the study period than those who did. One-third of enrollees who began treatment with buprenorphine received at least one behavioral therapy service; those who did not receive these services were less likely to continue treatment. Few enrollees received services paid for by Medicare aimed at sustaining access to treatment, such as counseling and care coordination in an office-based setting or initiation of treatment in the emergency department.

Related News Articles

Headline
The federal government shutdown will continue as the Senate Oct. 3 failed to adopt a government funding deal. The latest attempt to pass the House-passed…
Headline
The Centers for Medicare & Medicaid Services Sept. 30 issued a memo, through the Health Plan Management system, finalizing the Medicare Advantage…
Headline
The federal government shut down Oct. 1 following a failed Senate vote on the House-passed continuing resolution to fund the government by midnight Sept. 30.…
Headline
The AHA Sept. 29 sent recommendations to the Department of Health and Human Services and the Centers for Medicare & Medicaid Services to help ensure…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 26 that average premiums for Medicare Advantage and Part D would decline slightly in 2026.…
Headline
HHS awards $1.5 billion in opioid response grants to states, tribal communities The Department of Health and Human Services announced yesterday that it…